4D Molecular Therapeutics, Inc. (FDMT)
14.67
-0.24
(-1.61%)
USD |
NASDAQ |
Aug 28, 16:00
14.66
-0.01
(-0.07%)
After-Hours: 18:38
4D Molecular Therapeutics Enterprise Value : 501.13M for Aug. 27, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 27, 2026 | 501.13M |
| August 26, 2026 | 537.01M |
| August 25, 2026 | 545.85M |
| August 24, 2026 | 527.63M |
| August 21, 2026 | 551.92M |
| August 20, 2026 | 566.83M |
| August 19, 2026 | 603.27M |
| August 18, 2026 | 490.63M |
| August 17, 2026 | 480.97M |
| August 14, 2026 | 350.94M |
| August 13, 2026 | 321.13M |
| August 12, 2026 | 333.27M |
| August 11, 2026 | 311.19M |
| August 10, 2026 | 292.97M |
| August 07, 2026 | 271.43M |
| August 06, 2026 | 260.39M |
| August 05, 2026 | 245.48M |
| August 04, 2026 | 244.38M |
| August 03, 2026 | 234.99M |
| July 31, 2026 | 239.96M |
| July 30, 2026 | 233.89M |
| July 29, 2026 | 208.49M |
| July 28, 2026 | 221.74M |
| July 27, 2026 | 251.01M |
| July 24, 2026 | 233.89M |
| Date | Value |
|---|---|
| July 23, 2026 | 251.01M |
| July 22, 2026 | 283.03M |
| July 21, 2026 | 305.94M |
| July 20, 2026 | 290.21M |
| July 17, 2026 | 284.69M |
| July 16, 2026 | 276.40M |
| July 15, 2026 | 322.78M |
| July 14, 2026 | 323.89M |
| July 13, 2026 | 301.80M |
| July 10, 2026 | 357.57M |
| July 09, 2026 | 389.59M |
| July 08, 2026 | 396.77M |
| July 07, 2026 | 385.73M |
| July 06, 2026 | 380.21M |
| July 02, 2026 | 395.67M |
| July 01, 2026 | 378.55M |
| June 30, 2026 | 412.23M |
| June 29, 2026 | 302.90M |
| June 26, 2026 | 235.99M |
| June 25, 2026 | 231.81M |
| June 24, 2026 | 237.04M |
| June 23, 2026 | 235.99M |
| June 22, 2026 | 174.31M |
| June 18, 2026 | 134.59M |
| June 17, 2026 | 122.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amgen, Inc. | 279.55B |
| AnaptysBio, Inc. | 1.654B |
| Precision BioSciences, Inc. | 162.59M |
| Design Therapeutics, Inc. | 749.61M |
| Inhibrx Biosciences, Inc. | 1.871B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -72.94M |
| Revenue (Quarterly) | 3.781M |
| Total Expenses (Quarterly) | 76.72M |
| EPS Diluted (Quarterly) | -1.038 |
| Gross Profit Margin (Quarterly) | 44.75% |
| Profit Margin (Quarterly) | -1.93K% |
| Earnings Yield | -18.57% |
| Normalized Earnings Yield | -18.57 |